Эффективная и безопасная фармакотерапия при лечении HP-ассоциированных заболеваний желудка и двенадцатиперстной кишки

Abstract

The introduction of potent antisecretory drugs and eradication therapy (ET) of Helicobacter pylori (HP) [1, 2] in the last decades of the XX century has dramatically changed the pathogenic concept of such HP-associated gastric diseases as chronic gastritis (CG) type B and duodenal ulcer disease (DUD), as well as their treatment. In the nearest future we are likely to witness further improvement of the therapeutic methods suggested in the twentieth century. [3, 4].

Topics

Identifiers

DOI

10.21518/2079-701x-2014-4-55-59

Citations and references